Colorectal Cancer Specialty Channel

Colorectal Cancer

Specialty Channel

Conference Coverage

Association Between ctDNA and Disease-Free Survival Among Patients With Colorectal Cancer

01/28/2025

Allison Casey

Data from the BESPOKE CRC study found ctDNA to be prognostic of DFS within the molecular residual disease and surveillance windows among patients with stage II to stage III colorectal cancer.

Data from the BESPOKE CRC study...

01/28/2025

Oncology

Conference Coverage

Encorafenib Plus Cetuximab and Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

01/27/2025

Allison Casey

According to results from the BREAKWATER trial, encorafenib plus cetuximab and FOLFOX showed a significant improvement in response rate that was rapid and durable among patients with BRAF V600E-mutant metastatic colorectal cancer.

According to results from the...

01/27/2025

Oncology

Conference Coverage

Aspirin Reduces Risk of Colorectal Cancer Among Patients With PI3K Alterations

01/27/2025

Allison Casey

According to results from the ALASCCA trial, adjuvant daily aspirin treatment significantly reduced the rate of recurrence among patients with colorectal cancer with PI3K alterations.

According to results from the...

01/27/2025

Oncology

Conference Coverage

ctDNA Determines Prognosis, Celecoxib Benefit For Patients With Stage III Colon Cancer

01/27/2025

Allison Casey

According to data from the phase 3 CALGB/SWOG 80702 study, ctDNA may predict the benefit of adjuvant celecoxib to disease-free survival and overall survival for patients with stage III colon cancer.

According to data from the phase...

01/27/2025

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Potential New Standard of Care for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer

01/27/2025

Allison Casey

According to results from the phase 3, CheckMate 8HW trial, nivolumab plus ipilimumab demonstrated superior PFS compared with nivolumab monotherapy for patients with microsatellite instability-high, mismatch repair-deficient metastatic...

According to results from the...

01/27/2025

Oncology

Conference Coverage

Co-Formulated Favezelimab And Pembrolizumab Fails to Improve Survival for Metastatic Colorectal Cancer

01/27/2025

Stephanie Holland

Results from the phase 3 KEYFORM-007 trial demonstrated that co-formulated favezelimab and pembrolizumab failed to significantly improve survival compared to standard of care among patients with PD-L1-positive. microsatellite stable or...

Results from the phase 3...

01/27/2025

Oncology

Conference Coverage

ChatGPT Responses for Colon Cancer Information Were Relevant, Accurate

01/24/2025

Allison Casey

According to results from a study, the responses generated by ChatGPT for common patient questions about colon cancer closely aligned with the opinions of medical oncology experts, particularly when regarding symptoms, prevention, and...

According to results from a...

01/24/2025

Oncology

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland

Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...

Interim analysis results from...

01/06/2025

Oncology

News

FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer

12/20/2024

Allison Casey

On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.

On December 20, 2024, the US FDA...

12/20/2024

Oncology

Abigail Zamorano, MD, MPHS, UT Health Houston

Videos

Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer

10/08/2024

Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.

Abigail Zamorano, MD, MPHS,...

10/08/2024

Oncology

FDA Approval

FDA Approves Multitarget Stool DNA Test for Patients at Average Risk for Colorectal Cancer

10/07/2024

Stephanie Holland

Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.

Based on results from the BLUE-C...

10/07/2024

Oncology

News

Conference Coverage

Association Between ctDNA and Disease-Free Survival Among Patients With Colorectal Cancer

01/28/2025

Allison Casey

Data from the BESPOKE CRC study found ctDNA to be prognostic of DFS within the molecular residual disease and surveillance windows among patients with stage II to stage III colorectal cancer.

Data from the BESPOKE CRC study...

01/28/2025

Oncology

Conference Coverage

Encorafenib Plus Cetuximab and Chemotherapy for BRAF V600E-Mutant Metastatic Colorectal Cancer

01/27/2025

Allison Casey

According to results from the...

01/27/2025

Oncology

Conference Coverage

Aspirin Reduces Risk of Colorectal Cancer Among Patients With PI3K Alterations

01/27/2025

Allison Casey

According to results from the ALASCCA trial, adjuvant daily aspirin treatment significantly reduced the rate of recurrence among patients with colorectal cancer with PI3K alterations.

According to results from the...

01/27/2025

Oncology

Conference Coverage

ctDNA Determines Prognosis, Celecoxib Benefit For Patients With Stage III Colon Cancer

01/27/2025

Allison Casey

According to data from the phase 3 CALGB/SWOG 80702 study, ctDNA may predict the benefit of adjuvant celecoxib to disease-free survival and overall survival for patients with stage III colon cancer.

According to data from the phase...

01/27/2025

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab Potential New Standard of Care for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer

01/27/2025

Allison Casey

According to results from the...

01/27/2025

Oncology

Conference Coverage

Co-Formulated Favezelimab And Pembrolizumab Fails to Improve Survival for Metastatic Colorectal Cancer

01/27/2025

Stephanie Holland

Results from the phase 3...

01/27/2025

Oncology

Conference Coverage

ChatGPT Responses for Colon Cancer Information Were Relevant, Accurate

01/24/2025

Allison Casey

According to results from a...

01/24/2025

Oncology

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland

Interim analysis results from...

01/06/2025

Oncology

News

FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer

12/20/2024

Allison Casey

On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.

On December 20, 2024, the US FDA...

12/20/2024

Oncology

FDA Approval

FDA Approves Multitarget Stool DNA Test for Patients at Average Risk for Colorectal Cancer

10/07/2024

Stephanie Holland

Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.

Based on results from the BLUE-C...

10/07/2024

Oncology

Interactive Features

Quiz

Quiz: Incidence of Anal Cancer

05/18/2023

By approximately how much has the incidence of anal cancer has increased per year?

By approximately how much has...

05/18/2023

Oncology

Test Your Knowledge

Quiz: Does Pembrolizumab Plus CRT After FOLFOX Provide Benefit for LARC?

09/03/2021

True or false: Data from the NRG-GI002 trial show that neoadjuvant pembrolizumab plus CRT after FOLFOX treatment provides significant benefit as a combination therapy for patients with LARC.

True or false: Data from the...

09/03/2021

Oncology

Quiz

Quiz: Which Therapy Enhances Tumor Immunologic Response in LARC?

08/09/2021

Which therapy was found to enhance tumor immunologic response in patients with LARC?

Which therapy was found to...

08/09/2021

Oncology

Test Your Knowledge

Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer

04/22/2021

True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.

True or False: Cetuximab, a...

04/22/2021

Oncology

Test Your Knowledge

Quiz: Does Coffee Consumption Yield Benefit in CRC?

04/05/2021

True or False: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity.

True or False: Several compounds...

04/05/2021

Oncology

Test Your Knowledge

Quiz: What Are the 3 Current Modalities for Rectal Cancer?

03/24/2021

Which of the following are the 3 current modalities for rectal cancer?

Which of the following are the 3...

03/24/2021

Oncology

Test Your Knowledge

Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC

01/28/2021

True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.

True or false: Anlotinib has...

01/28/2021

Oncology

Test Your Knowledge

Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?

08/21/2020

True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.

True or false: Classifying and...

08/21/2020

Oncology

Test Your Knowledge

Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?

07/31/2020

True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.

True or false: Overall survival...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?

06/22/2020

True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.

True or False: MDMs in plasma...

06/22/2020

Oncology

Recent News

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland

Interim analysis results from...

01/06/2025

Oncology

News

FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer

12/20/2024

Allison Casey

On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.

On December 20, 2024, the US FDA...

12/20/2024

Oncology

FDA Approval

FDA Approves Multitarget Stool DNA Test for Patients at Average Risk for Colorectal Cancer

10/07/2024

Stephanie Holland

Based on results from the BLUE-C study, the FDA has approved the Cologuard Plus™ test for patients 45 years and older at average risk for colorectal cancer.

Based on results from the BLUE-C...

10/07/2024

Oncology

News

Adjuvant Aspirin Shows Protective Effect Among Patients With PIK3CA-Mutant Colon Cancer

10/02/2024

Allison Casey

The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.

The phase 3 SAKK 41/13 trial...

10/02/2024

Oncology

News

Neoadjuvant Nivolumab Plus Ipilimumab Showed Promise Among Patients With Locally Advanced Mismatch-Repair Deficient Colon Cancer

07/18/2024

Stephanie Holland

According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.

According to results from the...

07/18/2024

Oncology

News

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Overall Survival Among Patients With pMMR or Not MSI-High Metastatic Colorectal Cancer

07/11/2024

Stephanie Holland

Final analysis results from the phase 3 LEAP-017 trial demonstrated that lenvatinib plus pembrolizumab did not significantly improve overall survival compared to standard of care among patients with previously treated mismatch repair...

Final analysis results from the...

07/11/2024

Oncology

News

FDA Grants Accelerated Approval to Adagrasib With Cetuximab for Patients With KRAS G12C-Mutated Colorectal Cancer

06/21/2024

Based on results from the KRYSTAL-1 trial, the FDA has granted accelerated approval to adagrasib with cetuximab for patients with KRAS G12C-mutated colorectal cancer.

Based on results from the...

06/21/2024

Oncology

News

Laparoscopic Hemihepatectomy vs Open Hemihepatectomy Among Patients With Primary or Metastatic Liver Tumors

05/17/2024

Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major hemihepatectomy among patients with primary or metastatic...

Results from the ORANGE II PLUS...

05/17/2024

Oncology

News

Potential Benefits From Neoadjuvant Chemotherapy for Patients With Locally Advanced Colon Cancer

04/09/2024

Stephanie Holland

Results from the phase 3 OPTICAL study found potential benefits from neoadjuvant mFOLFOX6 or CAPOX among patients with locally advanced colon cancer.

Results from the phase 3 OPTICAL...

04/09/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

The FDA granted accelerated...

04/08/2024

Oncology

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology